About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.
- Order Number
- Package Size
- 100 µl (10 Tests)
XL 4q12 consists of a green-labeled probe hybridizing proximal to the FIP1L1 gene region at 4q12, an orange-labeled probe hybridizing to the CHIC2 gene region at 4q12 and an aqua-labeled probe hybridizing to the PDGFRA gene region at 4q12.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
The category ´myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1/JAK2´ of the revised 4th edition of the WHO classification defines three particular groups with rearrangements in PDGFRA, PDGFRB or FGFR1 and a provisional entity with PCM1/JAK2 rearrangement. The clinical manifestations within this category are numerous and heterogeneous and include myeloproliferative neoplasms, myelodysplastic syndromes as well as de novo or secondary mixed phenotype acute leukemia and lymphomas. Neoplasms with eosinophilia are associated with dysregulated tyrosine kinases, usually as a result of gene fusions. It is of great importance to identify the genes involved because aberrant tyrosine kinases react with varying sensitivity to tyrosine kinase inhibitors. Patients with PDGFRA and PDGFRB rearrangements are responsive to imatinib whereas FGFR1-related diseases are non-responsive. PDGFRA rearrangements are usually associated with chronic eosinophilic leukemia (CEL). The most frequent PDGFRA-related aberration is the interstitial deletion of the CHIC2 gene with breakpoints in the FIP1L1 and PDGFRA genes. The deletion of a fragment of about 800kb is resulting in the FIP1L1-PDGFRA fusion gene, a constitutively activated tyrosine kinase transforming hematopoietic cells. In FISH assays, the detection of CHIC2 deletion at 4q12 is a surrogate for the direct detection of the FIP1L1-PDGFRA fusion gene. Translocations with other partner genes, resulting in aberrant tyrosine kinase activity, are known. Involvement of PDGFRA can be detected by break apart FISH strategies.
- Myeloproliferative Neoplasm (MPN)
Two blue-green-orange fusion signals (2BGO).
Aberrant Cell (typical results):
One blue-green-orange (1BGO) and one blue-green (1BG) fusion signal indicating a deletion of CHIC2.
- Cools et al (2003) N Engl J Med 348:1201-1214
- Pardanani et al (2003) Blood 102:3093-3096
- Swerdlow et al (2017) WHO classification of tumors of haematopoietic and lymphoid tissues (revised 4th edition)